Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04700072 |
Title | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Merck Sharp & Dohme Corp. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ITA | ISR | FRA | ESP | CHE | AUS |